Abcam, ab314653, Anti-FLAP antibody [EPR27505-52] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FLAP antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Rat, Transfected cell lysate - Human, Transfected cell line - Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27505-52,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:ICC/IF, IHC-P, WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab314653 is the carrier-free version of
ab314652
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FLAP also known as ALOX5AP is an important protein in the leukotriene biosynthetic pathway. It functions mechanically as a membrane-associated protein that facilitates the transfer of arachidonic acid to 5-lipoxygenase (5-LOX) a critical step in the production of leukotrienes. FLAP has a molecular mass of approximately 18 kDa and is primarily expressed in cells of the myeloid lineage such as neutrophils monocytes and macrophages.
Biological function summary
FLAP plays an essential role in the inflammatory response and is a component of the leukotriene synthesis complex. This complex is responsible for the production of leukotrienes which are potent lipid mediators that contribute to inflammation and immune regulation. By regulating leukotriene synthesis FLAP supports processes like chemotaxis cell aggregation and smooth muscle contraction essential for the body's response to inflammation.
Pathways
The FLAP signaling pathway is integral to the leukotriene metabolic pathway. It facilitates the interaction between arachidonic acid and 5-LOX leading to the generation of leukotrienes such as LTA4 and LTB4. These molecules are involved in numerous processes including bronchoconstriction and migration of leukocytes. Proteins related to FLAP within this pathway include 5-LOX and LTC4 synthase which further convert leukotrienes into biologically active compounds.
FLAP is associated with asthma and cardiovascular diseases. Its role in producing leukotrienes links it to the pathogenesis of inflammatory conditions. Elevated levels of leukotrienes mediated by FLAP can exacerbate symptoms in asthma by causing bronchial constriction. In cardiovascular diseases FLAP-related pathway dysregulation can contribute to atherosclerosis development. Proteins connected to FLAP through these disorders include leukotriene receptor antagonists which are therapeutic targets for reducing leukotriene-mediated effects.